Sanofi (SNY +3.2%) and Genzyme (GENZ +3.2%) agree in principle on the broad terms of a deal,...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi (SNY +3.2%) and Genzyme (GENZ +3.2%) agree in principle on the broad terms of a deal, which includes a structure that might allow Genzyme investors to receive additional payments in the future if its leukemia drug Campath proves lucrative, WSJ reports. (earlier)